Q/C Technologies, Inc.

What they do

Per its latest 10-Q MD&A, QCLS is engaged in the development of a proprietary silicon photonic computing architecture for artificial intelligence (AI) inference, focused on its optical processing unit initiative (the "OPU Initiative"). The company says it has assembled a team of experts in AI, photonics, and advanced computing and intends to develop proprietary optical chip architectures addressing bandwidth, energy efficiency, and scalability bottlenecks for AI inference, while building a portfolio of foundational intellectual property through patent filings. In connection with this shift, the company relocated its headquarters to San Francisco, California, where it is establishing an integrated photonics laboratory. The company's SIC code remains In Vitro & In Vivo Diagnostic Substances, reflecting its legacy business.

Revenue drivers

• Legacy diagnostics business — The company's most recently reported annual revenue was $1.6M in 2019, declining from $3.4M in 2017; the filings provided do not identify active product lines generating revenue today.
• OPU Initiative / photonic AI inference chips — The 10-Q describes this as the company's current focus, but no revenue from optical computing products is disclosed in the financial data provided.
• Recent quarterly revenue — The latest quarterly revenue figures available are small and erratic — $420,812 (2019-09-30), $79,585 (2019-12-31), $363,515 (2020-03-31), and negative $1,888 (2020-06-30).

Recent performance

The most recent annual net losses reported are $4.0M (2023), $23.4M (2024), and $11.6M (2025). Operating cash flow was negative in each of the last five years, including -$9.0M in 2024 and -$9.1M in 2025. At June 30, 2026, the company reported total assets of $22.9M, total liabilities of $3.8M, shareholder equity of $16.1M, and cash and equivalents of $307,612. The company has not reported meaningful revenue since 2019; the latest quarterly revenue data available shows a negative $1,888 for the quarter ended 2020-06-30. Diluted EPS was -$8.66 in 2025 and -$1,080.87 in 2024.

Strategy

The company's stated strategy is to develop a proprietary silicon photonic computing architecture for AI inference through its OPU Initiative. It says it intends to address analog precision, nonlinear computation, and memory integration challenges through internally developed intellectual property and strategic collaborations. QCLS relocated its headquarters to San Francisco and is establishing an integrated photonics laboratory to accelerate research and development. The company also says it is building a portfolio of foundational intellectual property through patent filings.

Risks

• No meaningful revenue — The company has reported no significant revenue since 2019, and its latest quarterly revenue data shows a negative $1,888 for the quarter ended 2020-06-30.
• Going-concern / liquidity — Cash and equivalents were just $307,612 at 2026-06-30 against operating cash outflows of -$9.1M in 2025, indicating a need for additional financing.
• Strategic pivot execution — The company is attempting to shift from diagnostics into optical computing for AI inference, a capital-intensive field in which it has no disclosed revenue-generating products.
• Governance and management turnover — Recent 8-K filings report officer/director changes on 2026-09-11, 2026-01-23, 2025-11-14, 2025-10-06, and 2025-10-03, plus a material agreement termination on 2026-09-11.

Outlook

The 10-Q does not quantify future revenue, product timelines, or financing plans; it describes the company as focused on developing its photonic AI inference architecture and establishing a San Francisco photonics laboratory. Management's discussion is dominated by forward-looking language about the OPU Initiative rather than reported results. No specific guidance or committed funding amounts are disclosed in the excerpts provided.